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Introduction
65
The papillomaviruses (PVs), which are now officially recognized by the case-control studies from 9 countries evaluated 30 HPV types linked to cervical 81 cancer including fifteen HPV types classified as high-risk types (16, 18, 31, 33, 35, 39, 82 45, 51, 52, 56, 58, 59, 68, 73, and 82) ; three classified as probable high-risk types (26, 83 53, and 66); and twelve classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 84 72, 81, and CP6108) (19). High-risk types are associated with preneoplastic lesions and carcinomas, while low-risk types are typically associated with benign lesions.
86
Therefore, accurate HPV genotyping is essential for adequate patient classification 87 into low-risk or high-risk groups, and for determining whether the HPV infection is 88 persistent or transient. An HPV subset is also clearly implicated in the development of 89 human anal, vaginal, vulvar, penile, and oropharyngeal malignancies (9, 13, 28, 40) .
90
Moreover, anal HPV infections, especially high-risk types, were suggested to be 91 independently associated with HIV acquisition (30).
92
The HPV virion has a circular, is a powerful tool for microbial detection and confirmation (20, 22, 25, 32 Norcross, GA, USA). All samples were qualified using the NanoDrop 1000 (Thermo 153 Scientific, Waltham, MA, USA).
154
HPV detection and typing with consensus PCR (MY-PCR) and specific PCR
155
Consensus PCR targeting the HPV L1 region was performed using consensus MY09/ GenBank under accession numbers JQ902108-JQ902139.
170
HPV detection and typing with MassARRAY MALDI-TOF MS
171
Primer design and primary PCR. Representative HPV strains used for determination 172 of genotype groups are shown in Table S1 . Their sequences were obtained from Table S2 The HPV GenoArray test utilizes L1 consensus primers to simultaneously amplify 21 205 HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 206 68 and CP8304 (81) 
Results
211
Result of exploratory study 212 The analytical sensitivity of the PCR-MS assay was determined with plasmids In the 62 samples detected as single HPV infections ( (6, 11, 16, 18, 33, 35, 39, 40, 43, 45, 51, 52, 56, 59, 61, 66, 81, 82 and 89) . Two 12 samples were identified as HPV84 by consensus PCR, the HPV84 is outside of the 30 232 types included in the PCR-MS panel.
233
In the remaining 67 samples, the PCR-MS method detected multiple HPV types, 234 whereas consensus PCR followed by nucleotide sequencing detected only one HPV 235 type (See Table S3 for details). PCR-MS results which were scored as HPV positive 236 by L1 probes were confirmed by specific MY-PCR followed by nucleotide 237 sequencing of PCR products included 11 types (26, 31, 42, 44, 53, 54, 58, 68, 70, 72 238 and 73). All 30 types were detected by PCR-MS in these samples. Two HPV types 239 were detected in 28 samples, while 3-11 multiple HPV types were detected in 39 240 samples.
241
Results of validation test
242
A total of 135 invasive cervical tumor FFPE samples were analyzed using the (Table 3) . The 9 discordant samples tested positive by PCR-MS and negative 248 by GA included 3 internal control negatives (IC-N) 52 (4, 3.1%), 68 (4, 3.1%), 59 (3, 2.3%),56 (2, 1.5%), 82 (2, 1.5%), 39 (2, 1.5%), 66
267
(1, 0.8%), 42 (1, 0.8%) and 11 (1, 0.8%), 89 (1, 0.8%) , considering both single and 268 multiple infections (Table 4) . Several studies have pointed out that detection of the same carcinogenic HPV type 334 over time is particularly important for cervical carcinogenesis and HPV persistence is 335 a clinical marker and endpoint (7, 14, 26, 35) . Ronco et al. showed that HPV-based screening is more effective than cytology in preventing invasive cervical cancer (24). shows that HPV16 and HPV18 are the most oncogenic types (19, 29 In conclusion, our new assay is a reliable and high accurate method. It provides a 
